• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

簇集素是乳腺癌预后的生物标志物，且与免疫微环境相关。

Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment.

作者信息

Yang Ping, Yang Zhenyu, Dong Yanming, Yang Lin, Peng Shujia, Yuan Lijuan, Hu Xi'e, Chen Songhao, Tang Haili, Yang Xiaojun, Fan Dong, Zhao Huadong, Bao Guoqiang

机构信息

Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.

出版信息

Transl Cancer Res. 2023 Jan 30;12(1):31-45. doi: 10.21037/tcr-22-1882. Epub 2023 Jan 9.

DOI:10.21037/tcr-22-1882
PMID:36760385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9906057/
Abstract

BACKGROUND

It has been established that clusterin is involved in the invasion of immune cells in the tumor microenvironment, but it remains unknown how it promotes immune invasion in breast cancer.

METHODS

We used Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to assess the relation between expression of clusterin and immunoinfiltration-related marker genes. TIMER database was used to evaluate the expression of clusterin, and its relation to tumor immune invasion was examined. Based on Kaplan-Meier plotter database, we investigated the association between clusterin expression and prognosis in patients with cancer, and the impact of clinicopathological factors and cancer-related outcomes.

RESULTS

Clusterin expression was markedly associated with prognosis of a variety of tumors, specifically breast cancer. Enhanced clusterin expression was markedly associated with molecular typing of breast cancer and expression of multiple markers related to specific immune cell subsets.

CONCLUSIONS

These results indicate that clusterin is connected to prognosis of breast cancer patients and tumor immune cell infiltration. This demonstrates that clusterin may be a biomarker of immune cell recruitment into breast tumors and an important biomarker for immune cell infiltration; consequently being a valuable prognostic factor in breast cancer patients.

摘要

背景

已证实簇集素参与肿瘤微环境中免疫细胞的浸润，但它如何促进乳腺癌的免疫浸润仍不清楚。

方法

我们使用肿瘤免疫评估资源（TIMER）和基因表达谱交互分析（GEPIA）数据库来评估簇集素表达与免疫浸润相关标记基因之间的关系。使用TIMER数据库评估簇集素的表达，并检查其与肿瘤免疫浸润的关系。基于Kaplan-Meier绘图仪数据库，我们研究了簇集素表达与癌症患者预后之间的关联，以及临床病理因素和癌症相关结局的影响。

结果

簇集素表达与多种肿瘤，特别是乳腺癌的预后显著相关。簇集素表达增强与乳腺癌的分子分型以及与特定免疫细胞亚群相关的多种标志物的表达显著相关。

结论

这些结果表明簇集素与乳腺癌患者的预后和肿瘤免疫细胞浸润有关。这表明簇集素可能是免疫细胞募集到乳腺肿瘤中的生物标志物，也是免疫细胞浸润的重要生物标志物；因此是乳腺癌患者有价值的预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/2f2333556cff/tcr-12-01-31-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/e7824fcac752/tcr-12-01-31-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/7ff242add1d1/tcr-12-01-31-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/368f5bfc81d5/tcr-12-01-31-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/bd5e78f139b4/tcr-12-01-31-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/2f2333556cff/tcr-12-01-31-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/e7824fcac752/tcr-12-01-31-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/7ff242add1d1/tcr-12-01-31-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/368f5bfc81d5/tcr-12-01-31-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/bd5e78f139b4/tcr-12-01-31-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/9906057/2f2333556cff/tcr-12-01-31-f5.jpg

相似文献

1
Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment.簇集素是乳腺癌预后的生物标志物，且与免疫微环境相关。
Transl Cancer Res. 2023 Jan 30;12(1):31-45. doi: 10.21037/tcr-22-1882. Epub 2023 Jan 9.
2
LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.LPAR2 与头颈部鳞状细胞癌和肾透明细胞癌的不同预后和免疫细胞浸润相关。
Hereditas. 2022 Mar 4;159(1):16. doi: 10.1186/s41065-022-00229-w.
3
LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.LAYN 是胃癌和结肠癌的预后生物标志物，并与免疫浸润相关。
Front Immunol. 2019 Jan 29;10:6. doi: 10.3389/fimmu.2019.00006. eCollection 2019.
4
YAP1 is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Pancreatic Cancer.YAP1是一种预后生物标志物，与胰腺癌中的免疫细胞浸润相关。
Front Mol Biosci. 2021 Jun 2;8:625731. doi: 10.3389/fmolb.2021.625731. eCollection 2021.
5
FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers.纤连蛋白1是一种预后生物标志物，与胃癌中的免疫浸润相关。
Front Oncol. 2022 Aug 23;12:918719. doi: 10.3389/fonc.2022.918719. eCollection 2022.
6
The expression of is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker.[具体物质]的表达与基底样乳腺癌中的肿瘤浸润免疫细胞相关，并作为一种预后生物标志物。 （注：原文中“of”后面缺少具体内容）
Ann Transl Med. 2022 Jan;10(2):81. doi: 10.21037/atm-21-6611.
7
NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.NEFM 基因的 DNA 甲基化与乳腺癌的免疫浸润和生存相关。
Clin Epigenetics. 2021 May 17;13(1):112. doi: 10.1186/s13148-021-01096-4.
8
CTHRC1 is a Potential Prognostic Biomarker and Correlated with Macrophage Infiltration in Breast Cancer.CTHRC1是一种潜在的预后生物标志物，与乳腺癌中的巨噬细胞浸润相关。
Int J Gen Med. 2022 Jun 20;15:5701-5713. doi: 10.2147/IJGM.S366272. eCollection 2022.
9
ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors.ITGA5 是一种预后生物标志物，与胃肠道肿瘤的免疫浸润相关。
BMC Cancer. 2021 Mar 12;21(1):269. doi: 10.1186/s12885-021-07996-1.
10
Clusterin Is a Prognostic Biomarker of Lower-Grade Gliomas and Is Associated with Immune Cell Infiltration.簇集蛋白是低级别胶质瘤的预后生物标志物，与免疫细胞浸润有关。
Int J Mol Sci. 2023 Aug 29;24(17):13413. doi: 10.3390/ijms241713413.

引用本文的文献

1
Clusterin facilitates glioma progression via BCL2L1-dependent regulation of apoptotic resistance.聚集素通过依赖BCL2L1的凋亡抗性调节促进胶质瘤进展。
Front Mol Neurosci. 2025 Jun 18;18:1596021. doi: 10.3389/fnmol.2025.1596021. eCollection 2025.
2
Clusterin ameliorates diabetic atherosclerosis by suppressing macrophage pyroptosis and activation.聚集素通过抑制巨噬细胞焦亡和激活来改善糖尿病性动脉粥样硬化。
Front Pharmacol. 2025 Apr 23;16:1536132. doi: 10.3389/fphar.2025.1536132. eCollection 2025.
3
Applying integrated transcriptome and single-cell sequencing analysis to develop a prognostic signature based on M2-like tumor-associated macrophages for breast cancer.

本文引用的文献

1
Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer.簇集蛋白抑制可诱导胰腺癌细胞衰老而抑制增殖。
Ann Surg Oncol. 2022 Aug;29(8):4937-4946. doi: 10.1245/s10434-022-11668-0. Epub 2022 Apr 10.
2
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.三阴性乳腺癌的肿瘤微环境特征
Cancer Manag Res. 2022 Jan 3;14:1-17. doi: 10.2147/CMAR.S316700. eCollection 2022.
3
Immunotherapy for Triple-Negative Breast Cancer.三阴性乳腺癌的免疫疗法
应用综合转录组和单细胞测序分析来开发基于M2样肿瘤相关巨噬细胞的乳腺癌预后特征。
Discov Oncol. 2025 Mar 25;16(1):389. doi: 10.1007/s12672-025-02161-7.
4
Clusterin mediates hydroquinone-induced cytotoxic responses in HL-60 differentiated cells.簇集素介导对苯二酚诱导的HL-60分化细胞的细胞毒性反应。
Sci Rep. 2024 Dec 5;14(1):30402. doi: 10.1038/s41598-024-82140-0.
5
Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients.单细胞组学和机器学习的整合，为乳腺癌患者开发基于多胺代谢的风险评分模型。
J Cancer Res Clin Oncol. 2024 Oct 23;150(10):473. doi: 10.1007/s00432-024-06001-z.
6
Therapeutic Potential of Clusterin Inhibition in Human Cancer.簇集蛋白抑制在人类癌症中的治疗潜力。
Cells. 2024 Apr 10;13(8):665. doi: 10.3390/cells13080665.
7
Drug repositioning for immunotherapy in breast cancer using single-cell analysis.利用单细胞分析进行乳腺癌的免疫治疗药物重定位。
NPJ Syst Biol Appl. 2024 Apr 8;10(1):37. doi: 10.1038/s41540-024-00359-z.
8
Clusterin Is a Prognostic Biomarker of Lower-Grade Gliomas and Is Associated with Immune Cell Infiltration.簇集蛋白是低级别胶质瘤的预后生物标志物，与免疫细胞浸润有关。
Int J Mol Sci. 2023 Aug 29;24(17):13413. doi: 10.3390/ijms241713413.
9
The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing.簇集蛋白的来龙去脉：它在癌症、眼病和伤口愈合中的作用。
Int J Mol Sci. 2023 Aug 24;24(17):13182. doi: 10.3390/ijms241713182.
10
miRNA deregulation and relationship with metabolic parameters after Mediterranean dietary intervention in BRCA-mutated women.BRCA 突变女性接受地中海饮食干预后 miRNA 的失调及其与代谢参数的关系
Front Oncol. 2023 Apr 4;13:1147190. doi: 10.3389/fonc.2023.1147190. eCollection 2023.
Pharmaceutics. 2021 Nov 25;13(12):2003. doi: 10.3390/pharmaceutics13122003.
4
Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1.乳腺癌中免疫检查点抑制剂反应的预测生物标志物：超越肿瘤性PD-L1
Biomedicines. 2021 Dec 8;9(12):1863. doi: 10.3390/biomedicines9121863.
5
Breast cancer immunotherapy: current biomarkers and the potential of assays.乳腺癌免疫疗法：当前的生物标志物及检测方法的潜力
Curr Opin Biomed Eng. 2021 Mar;21. doi: 10.1016/j.cobme.2021.100348. Epub 2021 Sep 20.
6
structural analysis of secretory clusterin to assess pathogenicity of mutations identified in the evolutionarily conserved regions.分泌性聚集素的结构分析，以评估在进化保守区域鉴定出的突变的致病性。
J Biomol Struct Dyn. 2023 Feb;41(2):469-478. doi: 10.1080/07391102.2021.2007791. Epub 2021 Nov 25.
7
The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review.簇集素在非小细胞肺癌中的多重作用及治疗潜力：一项叙述性综述
Transl Lung Cancer Res. 2021 Jun;10(6):2683-2697. doi: 10.21037/tlcr-20-1298.
8
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.FLNA 和 CLU 在 PBMCs 中的表达可作为肝细胞癌的新型筛查标志物。
Sci Rep. 2021 Jul 21;11(1):14838. doi: 10.1038/s41598-021-94330-1.
9
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.一线阿替利珠单抗联合白蛋白紫杉醇治疗不可切除、局部晚期或转移性三阴性乳腺癌：IMpassion130 最终总生存分析。
Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
10
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.